ImmunoVaccine Up 24% On Deal With Gilead Sciences By: Benzinga via Benzinga February 27, 2015 at 12:50 PM EST ImmunoVaccine Inc. (CVE: IMV) granted an exclusive development and commercialization license for its anthrax and Ebola vaccines ... Read More >> Related Stocks: Gilead Sciences